author-photo

Anastasia G Eleftheraki

Boehringer Ingelheim

2

Papers

33

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker parameters in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

2019 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (23)
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases

2018 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (10)